We serve Chemical Name:potassium,4-nitrobenzoate CAS:15922-01-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:potassium,4-nitrobenzoate
CAS.NO:15922-01-7
Synonyms:Potassium 4-Nitrobenzoate;N0160;Potassium 4-nitrobenzoate;potassium p-nitrobenzoate;4-Nitro-benzoesaeure,Kalium-Verbindung;4-Nitrobenzoic Acid Potassium Salt;p-NO2-C6H4COOK;4-Nitrobenzoic Acid PotassiuM Salt;4-nitro-benzoic acid,potassium-compound;4-Nitrobenzoic acid potassium
Molecular Formula:C7H4KNO4
Molecular Weight:205.20900
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:359.1ºC at 760mmHg
Density:N/A
Index of Refraction:
PSA:85.95000
Exact Mass:204.97800
LogP:0.48150
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Potassium 4-Nitrobenzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Nitrobenzoic acid potassium physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N0160 Use and application,4-Nitrobenzoic Acid PotassiuM Salt technical grade,usp/ep/jp grade.
Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. potassium,4-nitrobenzoate manufacturer However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period. potassium,4-nitrobenzoate supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. potassium,4-nitrobenzoate vendor In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. potassium,4-nitrobenzoate factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.
